Excellent results form this study!
What are shareholders thoughts on only a 3 year market exclusivity impacting the valuation ?
I do expect this business to be taken over slightly before final FDA approval by a big pharma, but have concerns that 3 years may not be long enough.
It is true that the first product to market will still maintain roughly 50% of its market share in the first year out of exclusivity, however I worry this limits the value of the company from an acquisition standpoint.
Ann: SPONTAN achieves positive clinical study results, page-70
Add LTP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
82.5¢ |
Change
-0.035(4.07%) |
Mkt cap ! $58.08M | |||
| Open | High | Low | Value | Volume |
| 87.0¢ | 87.0¢ | 82.5¢ | $183.7K | 218.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 60820 | 82.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.5¢ | 2373 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| LTP (ASX) Chart |